Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capability of Tofacitinib or Etanercept to Accelerate Clinical Relevant Tapering of Non-steroidal Anti-inflammatory Drugs (NSAID) and Treat-to-target Guided De-escalation of Corticosteroids in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Previous csDMARD Therapy (AcceleRAte)

NCT04485325 is registered in ClinicalTrials.gov with Dr. Frank Behrens as lead sponsor.

NCT NCT04485325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04485325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capability of Tofacitinib or Etanercept to Accelerate Clinical Relevant Tapering of Non-steroidal Anti-inflammatory Drugs (NSAID) and Treat-to-target Guided De-escalation of Corticosteroids in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Previous csDMARD Therapy (AcceleRAte)
Lead sponsor
Dr. Frank Behrens
Phase
Phase 4
Overall status
Completed
Start date
November 4, 2019
Completion date
March 31, 2024
Enrollment
92 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatic arthritis